Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Merck & Co., Inc. (MRK) Price & Performance

Lithium Americas CorpTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Merck & Co., Inc. — how do they compare? Lithium Americas Corp trades at $3.25 (market cap $1.18B), while Merck & Co., Inc. trades at $132.88 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 272.7× Lithium Americas Corp's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

LACMRK
Market Cap
$1.18B$321.77B
Sector
Basic MaterialsHealth
52-Week High
$10.05$131.84
52-Week Low
$2.71$77.60
Enterprise Value
$1.29B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK